CRN strongly supports the creation of a mandatory product listing (MPL) housed at FDA to provide transparency to regulators, retailers and consumers alike.
Latest news
JULY 29, 2024: CRN opposes the latest MPL legislation in its current form, but remains committed to the concept
❌ It contains the expanded requirement that manufacturers provide FDA with a list of all their website claims for a new product—beyond the label and package insert information— which is burdensome on industry and exceeds the original objective of the registry to provide FDA with a current snapshot of products on the market.
❌ CRN also notes that requiring companies to submit copies of their website claims does little to address concerns over tianeptine.
▶ ▶ YES, BUT ▶ ▶ in its letter to Sen. Durbin, CRN affirmed its commitment to transparency through a listing program and said it remains hopeful that further discussions will lead to a compromise that addresses these concerns and targets bad actors in the marketplace as intended.
Previous reporting
MARCH 2024: Opinion: Mandatory Listing—Facts, Fiction and Conspiracies
Some people see conspiracies around every corner. And others manufacture them for political gain. CRN President & CEO Steve Mister addresses misrepresentations of the proposal in a NutraIngredients-USA
JAN. 3, 2023 PRESS RELEASE: Dietary Supplement Listing Exclusion Missed Opportunity in 117th Congress, But Concept Here to Stay
DECEMBER 20, 2022 PRESS RELEASE: CRN sets the Record Straight about Dietary Supplement Listing
DECEMBER 7: Sen. Durbin Calls on Senate Colleagues to Include Measures to Regulate Dietary Supplement in Omnibus Appropriations Bill | VIDEO
OCTOBER 13: Gottlieb & McClellan in JAMA Health Forum—Reforms Needed to Modernize the US Food and Drug Administration’s Oversight of Dietary Supplements, Cosmetics, and Diagnostic Tests
SEPTEMBER UPDATE
NEW: CRN Disappointed, but Remains Committed to Product Listing for Dietary Supplements
- Congressional leadership with jurisdiction over the FDA user fee reauthorization process have aligned on a version of the FDA Safety and Landmark Advancements (FDASLA) Act that does not include dietary supplement Mandatory Product Listing (MPL), diagnostics, or cosmetics.
- What's next: There is still a chance for MPL to be part of an end-of-year omnibus package. CRN will continue to work to find a legislative vehicle for MPL while advocating for the priorities our board of directors affirmed. “There is still some very strong interest in doing these other FDA-related things before the end of the session,” said CRN’s President and CEO Steve Mister, commenting in coverage from NutraIngredients-USA.
AUGUST UPDATE
- CRN is still at the table negotiating the details of mandatory product listing (MPL) legislation, President & CEO Steve Mister assured members in an open letter to the industry, as reported by Nutrition Insight and Nutritional Outlook.
Help CRN advance efforts to enact federal legislation that would establish an MPL for dietary supplements in the U.S. market. Contact your elected officials—be heard! Find your member of Congress.
Recent publications on policy-making details:
- CRN says furor about new prohibited act is much ado about nothing Covington & Burling's Miriam Guggenheim and CRN's Steve Mister, NutraIngredients, July 2022
- Institutionalizing Visibility and Enforcement—The Dietary Supplement Listing Act of 2022 CRN's Steve Mister, Healthcare Business Today, July 2022
- Op-Ed: 80% of Americans take dietary supplements. Better oversight and safety are musts President & CEO Steve Mister in the Indy Star
- The FDA needs more information on supplements. Consumers’ safety is at risk. The Pew Charitable Trusts Liz Richardson in the Chicago Tribune
JUNE 14 UPDATE: CRN Steadfast to Secure Responsible Mandatory Product Listing for Dietary Supplements
MAY 27 UPDATE: CRN Objects to Missing Protections in FDA Safety and Landmark Advancements Act
WATCH OUR MAY 2022 TOWN HALL
DOWNLOAD THE SLIDE DECK
READ THE SENATE BILL
LEARN MORE ABOUT MANDATORY PRODUCT LISTING FOR SUPPLEMENTS:
MAY 16: What If There Were A Registry?—Steve Mister in CRN's Supplemental blog
APRIL 29: Mandatory Product Listing: It Won’t 'Wash the Windows' Either!—Steve Mister in NutraIngredients-USA
APRIL 27: Ignore the Red Herrings: Myths & Facts about Mandatory Product Listing—Steve Mister in Nutraceuticals World
APRIL 26: Durbin, Braun introduce legislation to improve safety and ensure transparency of dietary supplement industry
Additional resources and coverage:
-
Mandatory Product Listing Reality Check Deck
-
CRN's blog, Supplemental: Pondering New Platforms, Straw Men, and Driver’s Licenses
-
Short Briefs with Josh Long, special edition: Trade associations debate mandatory product listing
More:
- DSQC: The time is now to enact the mandatory product listing
- Pew: Congress must pass mandatory product listing legislation to protect consumers
- CRN Daily Supplement—UNLOCKED EDITION: Mandatory product listing could see movement in 2022, stakeholders say
- Stakeholder group members explain support for mandatory product listing
- What's next for the supplement industry?
Things to Know About Mandatory Product Listing
Learn how the CRN-spearheaded Supplement OWL is a model for product listing.
Catch up on CRN's thought leadership on MPL in the articles below:
Stop the sale of bogus supplements as a cure or treatment for COVID-19
by Julia Gustafson with Liz Richardson of The Pew Charitable Trusts in The Hill
A Mandatory Dietary Supplement Registry: Transparency as ‘disinfectant’
by Steve Mister in RAPS Regulatory Focus
Mandatory Product Listing: Beneficial, or Burdensome?
by Steve Mister in WholeFoods Magazine